Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy
Authors:
- Robert L MurphyRMRobert L Murphy
- Baiba BerzinsBBBaiba Berzins
- Carlos ZalaCZCarlos Zala
- Carl FichtenbaumCFCarl Fichtenbaum
- Michael P DubeMDMichael P Dube
- Giovanni GuaraldiGGGiovanni Guaraldi
- Francesca TorrianiFTFrancesca Torriani
- Elizabeth BelseyEBElizabeth Belsey
- Carol MitchellCMCarol Mitchell
- James H SteinJSJames H Stein
- 27 March 2010
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 24 (6) , 885-890
Abstract
Protease inhibitors and other antiretroviral drugs have been associated with dyslipidemia, endothelial dysfunction, and increased cardiovascular disease risk. The protease inhibitor atazanavir has an advantageous lipid profile; we studied its effects on arterial function and other metabolic and inflammatory cardiovascular disease risk factors. Prospective, randomized, multinational trial in HIV-infected patients receiving stable protease inhibitor-based therapy with plasma HIV RNA less than 500 copies/ml and fasting low-density lipoprotein cholesterol more than 130 mg/dl, or triglycerides more than 200 mg/dl. Patients were randomized to continue their current protease inhibitor or switch the protease inhibitor to atazanavir and continue ritonavir if given as a protease inhibitor booster for 24 weeks. Brachial artery flow-mediated dilation, lipoproteins, and inflammatory and metabolic markers were measured at baseline, week 12, and week 24. Median changes within (signed rank test) and between (Wilcoxon test) arms were calculated. Twenty-six patients switched to atazanavir (all continued on ritonavir); 24 remained on their protease inhibitor regimen. Median CD4 cell count was 499 cells/mul, total cholesterol 204 mg/dl, low-density lipoprotein cholesterol 122 mg/dl, and triglycerides 244 mg/dl. There were no significant changes in flow-mediated dilation after 12 and 24 weeks. At 24 weeks, significant changes in the atazanavir vs. continued protease inhibitor group were observed for total cholesterol (-25 vs. +1.5 mg/dl, P = 0.009), triglycerides (-58 vs. +3.5 mg/dl, P = 0.013), and nonhigh-density lipoprotein cholesterol (-27 vs. -0.5 mg/dl, P = 0.014). In dyslipidemic individuals with suppressed HIV RNA on stable therapy, changing the protease inhibitor to atazanavir/ritonavir for 24 weeks improved lipids; however, endothelial function, inflammatory, and metabolic markers did not change.Keywords
This publication has 21 references indexed in Scilit:
- No Impairment of Endothelial Function or Insulin Sensitivity with 4 Weeks of the HIV Protease Inhibitors Atazanavir or Lopinavir‐Ritonavir in Healthy Subjects without HIV Infection: A Placebo‐Controlled TrialClinical Infectious Diseases, 2008
- Endothelial Function in Human Immunodeficiency Virus-Infected Antiretroviral-Naive Subjects Before and After Starting Potent Antiretroviral TherapyJACC, 2008
- Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trialHeart, 2008
- Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaborationThe Lancet, 2008
- Severe Impairment of Endothelial Function with the HIV-1 Protease Inhibitor Indinavir is not Mediated by Insulin Resistance in Healthy SubjectsCardiovascular Toxicology, 2008
- Class of Antiretroviral Drugs and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2007
- Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitorsAmerican Heart Journal, 2004
- Interaction between a genetic variant of the platelet fibrinogen receptor and fibrinogen levels in determining the risk of cardiovascular eventsAmerican Heart Journal, 2004
- Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected menAIDS, 2003
- Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility.Heart, 1995